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Many biological assays are employed in virology to quantify parameters of interest. Two such classes of
assays, virus quantification assays (VQA) and infectivity assays (IA), aim to estimate the number of viruses
present in a solution, and the ability of a viral strain to successfully infect a host cell, respectively. VQAs
operate at extremely dilute concentrations and results can be subject to stochastic variability in virus-cell in-
teractions. At the other extreme, high viral particle concentrations are used in IAs, resulting in large numbers
of viruses infecting each cell, enough for measurable change in total transcription activity. Furthermore, host
cells can be infected at any concentration regime by multiple particles, resulting in a statistical multiplicity of
infection (SMOI) and yielding potentially significant variability in the assay signal and parameter estimates. We
develop probabilistic models for SMOI at low and high viral particle concentration limits and apply them to the
plaque (VQA), endpoint dilution (VQA), and luciferase reporter (IA) assays. A web-based tool implementing
our models and analysis is also developed and presented. We test our proposed new methods for inferring ex-
perimental parameters from data using numerical simulations and show improvement on existing procedures in
all limits.
I. INTRODUCTION
Understanding viral dynamics is an important task in
medicine, epidemiology, public health, and, in particular, for
the development of antiviral therapies and vaccines. Drugs
that hinder viral infection include blockers of viral entry into
the host cell [1–6] and inhibitors of genetic activity and pro-
tein assembly inside the cytoplasm and nucleus [7–9]. Mech-
anistic models of drug action have recently emerged as useful
tools in helping design ad-hoc experiments to study drug effi-
cacy and in interpreting results [10–13]. Mathematicalmodels
typically assume prior knowledge of given physical quantities
pertaining to the virus, host cell, or the biological assay be-
ing studied. Once these parameters are assigned, viral and
cell population dynamics and their statistical properties can
be predicted. Among the different experimental assays, one
often seeks to evaluate the number of virus particles in a stock
solution or the number of viruses that have successfully in-
fected host cells [6, 14–19].
In the case of virus quantification assays (VQA), perform-
ing repeated controlled experiments on viral dynamics or
comparing results across multiple studies requires knowing
how many viruses are present in the initial stock solution of
each experiment [4, 5]. Furthermore, antigens that induce
immune responses against viral infections may be engineered
from viral components such as capsid proteins, viral enzymes,
and genetic vectors [20], and may be used in the development
of vaccines. Being able to determine the exact number of
virus-derived antigens helps control the efficacy of vaccines
and optimize yield [21–23].
Given the central role of VQAs, several assays have been
designed to estimate viral particle counts. These include
plaque [24] and endpoint dilution [23, 25] assays, which will
be discussed in more detail in the remainder of this work. For
now, we note that these assays involve repeatedly diluting an
initial solution of virus particles in the presence of a layer of
plated cells, until viral concentrations are low enough that the
dynamics of an individual virus can be extrapolated. At these
low particle counts, however, the discrete nature of the infec-
tion process cannot be neglected and can cause substantial
discrepancies when replicating experiments. Average quan-
tities are not necessarily representative, and a more in-depth
approach in quantifying virus-cell interactions is necessary.
Infectivity assays (IA), on the other hand, aim to quan-
tify the number of viruses that have successfully infected host
cells under varying antiviral drug environments [14–16]. IAs
may measure the total transcription activity across all cells,
such as the luciferase reporter assay [15, 26], or may count
the number of host cells that were successfully infected, such
as the enzyme-linked immunosorbent assay (ELISA) and the
immunofluorence assay with fluorescence activated cell sort-
ing (FACS) [4, 14, 15, 27]. These assays are performed using
undiluted solutions with large numbers of viral particles, re-
ducing stochastic variability. The average number of viruses
that infect a cell is estimated as the ratio of the number of
viruses in solution to the number of plated cells, a quantity
known as the multiplicity of infection (MOI) [19]. However,
each cell may be infected by different numbers of viruses dis-
tributed around the average given by the MOI. In these cases,
one may be interested in the complete probability distribution
for the number of virus infections in each plated cell and in
the related statistical variance.
In this paper, we derive a probability model for the distribu-
tion of viral infections per host cell, which we call the statis-
tical multiplicity of infection (SMOI). The SMOI can be used
as a starting point to help estimate the number of viral par-
ticles in solution in VQAs, and to determine a viral strain’s
ability to successfully infect host cells in IAs. In Section IIA,
we present the mathematical foundations for the SMOI in the
two experimentally relevant parameter regimes of small and
large viral particle counts and derive a probability model for
the total number of infected cells under any dilution level. In
Section IIIA, we apply our models to the plaque assay and
formulate a new method of analyzing plaque count data. In
Section III B we employ a special case of the derived prob-
2System Parameters
N0 Number of viruses
N Number of infections
M Number of host cells
M∗ Number of infected cells
Mr Number of cells infected
by exactly r viruses
Q Particle to PFU ratio
D Dilution factor
FIG. 1: A typical assay includes a plate of M host cells inoculated
with a solution ofN0 viruses. Each viral particle has some probabil-
ity of infection and the total number N of infections are distributed
to theM∗ infected cells. The probability of infection is roughly es-
timated with the reciprocal of the a priori measured particle to PFU
ratio Q.
ability distribution to the endpoint dilution assays and com-
pare our results to those arising from traditional titration tech-
niques such as the Reed and Muench [28] and Spearman-
Karber methods [29]. In Section III C, we use the large parti-
cle limit of our model to describe the luciferase reporter assay.
Lastly, a discussion of our results, a side-by-side comparison
with existing methods, and a link to web-based data analy-
sis tools are provided in Section IV. Mathematical appendices
and further discussion of experimental attributes such as cell
size variability, coinfection, viral interference, and optimal ex-
perimental design using parameter sensitivity analysis are pre-
sented in the Supplemental Information (SI).
II. METHODS
A. Probabilistic Models of Statistical Multiplicity of Infection
(SMOI)
A typical viral assay is initiated by laying a monolayer of
M cells on the bottom of a microtiter well, as illustrated in
Fig. 1 [17, 24, 25]. Although variability exists among experi-
ments,M is often set within the range of 104–105 [14, 26] and
is assumed to be a known experimental parameter. A super-
natant containing N0 virus particles in the range of 10
5–107
[24–26], is then added to the microtiter well. While, theo-
retically, all N0 particles are capable of infection, not all will
successfully infect a cell. Since infection of a host cell re-
quires a complex sequence of biochemical processes that may
include receptor binding, membrane fusion, reverse transcrip-
tion, nuclear pore transport, and DNA integration [10, 19],
virus particles that fail at one or several of these sequential
steps lead to abortive infections. To differentiate, the parti-
cles that do succeed are called infectious units (IU) or plaque
forming units (PFU). We will denote the number of IUs as
N ≤ N0. Depending on the strain of virus, the particular ex-
perimental protocol used, and specific conditions of the assay,
the random quantityN is distributed according to N0 and the
overall effective probability that an arbitrary viral particle suc-
cessfully infects a host cell. A proxy that is typically used in
place of this effective probability is the “particle to PFU ratio”
Q, an experimentally determined parameter that quantifies, on
average, the minimum number of particles required to ensure
at least one infected cell [30, 31]. Q is often treated as an a
priori measured quantity, primarily associated with the par-
ticular strain of virus being studied. Low values of Q, such
as with poliovirus (Q = 30) [31], have a high likelihood of
successful infection compared to viruses with large Q, such
as HIV-1 (Q = 107) [32]. Thus, the reciprocal Q−1 can be
interpreted as the probability for a single virus to infect a host
cell. Assuming an initial stock of N0 particles, the discrete
probability density function of N is
Pr (N = n|N0, Q) =
(
N0
n
)(
Q−1
)n (
1−Q−1
)N0−n
,
(1)
which defines a binomial distribution with parametersN0 and
Q−1. Although we assume Q to be a priori known, in actu-
ality, the probability of a virus successfully infecting a host
is highly dependent on the methods used to harvest the virus
stock, the experimental parameters of the assay, the host re-
ceptor concentrations and binding rates, and the dynamics of
the physiological processes leading to infection [30, 33]. A
thorough investigation into these processes would be neces-
sary to mechanistically modelQ and is outside of the scope of
this paper. However, we will discuss in Section IV how, with
direct measurements of certain other parameters, especially
N0, our derived methods may also be used to inferQ.
We assume each viral particle in solution acts indepen-
dently of others and that host cell infection attempts are ran-
dom events. At high ratiosN0/M of particles to cells, a quan-
tity referred to as the “multiplicity of infection” (MOI), it be-
comes increasingly probable for more than one IU to infect
the same host cell. We defineM0 as the count of cells not in-
fected by any IU,M1 as the count of cells infected by exactly
one IU, up toMN , the number of cells infected by all N IUs.
The statistical multiplicity of infection (SMOI) is defined as
the ensemble of cell counts {M0,M1, · · · ,MN}. Note that
two constraints must hold:
∑N
r=0Mr = M to account for
all infected and un-infected cells, and
∑N
r=0 rMr = N for
conservation of the total number of IUs. If we assume all M
cells are of identical size and volume, they carry equal prob-
ability of being infected by a particular virus. Thus, evaluat-
ing the probability distribution thatMr takes on the valuemr
reduces to the well-known occupancy problem of randomly
placing balls into identical urns [34] and we derive
3Pr(Mr = mr|M,N) =
M∑
j=mr
(
j
mr
)(
M
j
)(
N
r, · · · , r, (N − rj)
)
(−1)j−mr (M − j)
N−rj
MN
, (2)
where the r term is repeated j times in the lower argument of
the multinomial coefficient. The derivation of Eq. 2 is detailed
in Appendix A in the SI and an investigation into the effects
of inhomogeneous cell sizes is presented in Appendix B. Fur-
thermore, in Appendix A, we derive the expected value and
variance ofMr as
E [Mr] = M
(
N
r
)(
1
M
)r (
1−
1
M
)N−r
, (3)
and
Var [Mr] = M
(
N
r
)(
1
M
)r (
1−
1
M
)N−r
+
M(M − 1)N !(M − 2)N−2r
(r!)2(N − 2r)!MN
−
M2(N !)2(M − 1)2N−2r
(r!)2 [(N − r)!]
2
M2N
. (4)
Note that the variance is equal to the expected value with
two additional correction terms that cancel each other as N
andM increase, indicating the probability distribution ofMr
is Poisson-like for large N and M . A plot of a representa-
tive probability distribution and a test of agreement between
our analytical result and numerical simulation is provided in
Fig. 2.
We also derive the joint probability Pr(M0 =
m0, · · · ,MN = mN |M,N) that the SMOI
{M0,M1, · · · ,MN} takes on the set of values
{m0,m1, · · · ,mN} as
Pr(M0 = m0, · · · ,MN = mN |M,N) =
1
MN
(
M
m0,m1, · · · ,mN
)(
N
0, · · · , 0, 1, · · · , 1, · · · , N, · · · , N
)
=
M !N !
MN
N∏
r=0
1
mr! (r!)
mr . (5)
The first and second multinomial expressions enumerate the
degeneracy of how theM identical cells are distributed across
the configuration {m0, · · · ,mN} and how the N identical
IUs are chosen for those cells respectively. Although the
second expression in Eq. 5 is more succinct, it must be ex-
plicitly conditioned on the constraints
∑N
r=0mr = M and∑N
r=0 rmr = N .
The expressions in Eqs. 2 and 5 provide an exact discrete
description of the stochasticity of the MOI, but are computa-
tionally expensive to evaluate for large values of N and M .
In a typical virology experiment, the number of viral particles
N0 and host cells M are large enough for certain asymptotic
methods to be applicable. Furthermore, for intermediate val-
ues of Q, and based on Eq. 1, the expected number of IUs N
would be similarly large. We can thus take the mathematical
limit N,M → ∞ while keeping the ratio µ = N
M
fixed and
approximate Eq. 2 as:
Pr(Mr = mr|M,N) ≈
1
mr!
[
Mµre−µ
r!
]mr
exp
[
−
Mµre−µ
r!
]
.
(6)
Eq. 6 implies that Mr is Poisson-distributed with mean and
variance
E[Mr] = Var[Mr] ≈
Mµre−µ
r!
. (7)
A mathematical justification of Eq. 6 is given in Appendix A
and comparisons of Eq. 6 and the analytical result in Eq. 2 to
simulations are shown in Fig. 3. Under the same largeM,N
limit and using Eq. 6, we show in Appendix A
Pr(M0 = m0, · · · ,MN = mN |M,N)
≈
∏N
r=0Pr(Mr = mr|M,N),
(8)
which implies that as M,N → ∞, the random variables
M0,· · · , MN are independently distributed. In the next sec-
4FIG. 2: (a) A collection of curves of the probability of finding mr
cells that have been infected by exactly r IUs given a total number of
IUsN = 100 and a total number of cellsM = 10 using Eq. 2. With
N/M = 10, we expect very few cells to be uninfected, resulting
in the probability distribution concentrated close to 0 for low values
of r. Similarly, we expect few cells to be infected by a very large
number of IUs, accumulating the probability distribution close to 0
for large r. Only at intermediate values of r ≈ N/M = 10 we ob-
serve a Poisson-like distribution. (b) We perform a numerical study
to show empirically that our analytical result in Eq. 2 matches the sta-
tistical frequency of virus-cell counts from a simulation ofN = 100
IUs being randomly assigned toM = 10 cells. The square sum error
between the simulated proportions and the analytical result was cal-
culated with increasing numbers of iterations of the simulation. For
iterations around 106, our square sum error is on the order of 10−6,
indicating strong agreement between our model and simulation.
tion, we will apply results of our probability model of SMOI
to the case of a repeatedly diluted solution of virus particles,
a procedure used in many VQAs.
B. Serial Dilution
Low viral particle concentrations in assays are typically ob-
tained via serial dilution processes in order to increase the sen-
sitivity to individual viral infections [4, 24, 25]. The initial
viral stock containingN0 particles is diluted by a fixed factor
of D and the process is repeated dmax times. At each dilu-
tion number d, an assay can be performed to determine if the
concentration of virus particles in the diluted solution is suf-
ficient to generate a qualitative signal of infection, known as
a “cytopathic effect” (CE). For example, the diluted stock can
be administered in vivo to a model organism such as a mouse.
The mouse’s death would indicate that at least one lethal unit
of the virus was present at that dilution level. Alternatively, an
in vitro assay can be carried out to measure a signal that, for
example, quantifies the exact number of plated cells that were
successfully infected. To model these assays, we first define
M∗ as the number of host cells infected by at least one IU and
that are capable of producing new viruses. In Appendix A
we derive the discrete probability density function for finding
M∗ = m infected cells at a given dilution number d and find
Pr (M∗ = m) =
(
M
m
) [
1− exp
(
− N0
QMDd
)]m
× exp
(
− N0
QMDd
)M−m
.
(9)
Eq. 9 shows that the number of infected cells M∗ is binomi-
ally distributed with expected value
E[M∗] = M
[
1− exp
(
−
N0
QMDd
)]
, (10)
and variance
Var[M∗] =M
[
1− exp
(
−
N0
QMDd
)]
exp
(
−
N0
QMDd
)
.
(11)
We can define the probability of observing a CE at dilution
number d as the probability of finding one or more infected
cells:
Pr(“Cytopathic effect”) ≡
M∑
m=1
Pr(M∗ = m)
= 1− exp
(
−
N0
QDd
)
. (12)
The definition we use in Eq. 12 assumes an in vitro assay that
can exhibit a cytopathic signal after a single cell infection or
more. For in vivo assays, the probability thatm infected cells
are sufficient for a CE will depend on many complex phys-
iological factors such as immune pressure, in-host viral evo-
lution, and virion burst size [35]. A plot of how the initial
particle countN0 and dilution factorD effect the characteris-
tic functional form of Eq. 12 are shown in Fig. 4. Although
both Eqs. 9 and 12 assume each IU contains all viral genes re-
quired for in-host replication, an extended probability model
that factors in genetic mutation and degradation is provided in
Appendix C. Furthermore, for the case of retroviruses, infec-
tious processes inside the host cytoplasm may be suppressed
by previous infections, known as viral interference, and is ex-
plored in Appendix D. In Section III A, we will use Eq. 9 to
analyze the plaque assay. Eq. 12 will be used for “binary” as-
says that are only concerned with the presence or absence of a
CE such as the endpoint dilution assay, which we will explore
in Section III B.
III. RESULTS AND DISCUSSION
A. Plaque Assay
The plaque assay is an example of a virus quantification
assay (VQA) where the objective is to infer the total number of
virusesN0 present in a solution assuming the PFU to particle
ratio Q has been independently measured and estimated [24,
25, 36]. After d serial dilutions, the viral stock is added to
a monolayer of M cells and a layer of agar gel is added to
the well to inhibit the diffusion of virus particles in the plate.
If a virus successfully infects a host cell, the agar will limit
the range of new infections to the most adjacent cells. Viral
infection thus spreads out radially from the initial nucleation
infection and forms a visible discoloration in the plate called
a “plaque.” For high particle concentrations, the number of
plaques formed may be large enough to cover the entire plate
5FIG. 3: Heat maps of the probability distribution Pr (Mr = mr|M,N) of finding mr cells that have been infected by exactly r IUs given
a total number of viruses N = 100 and M = 10 cells. (a) The statistical frequency of virus-cell counts after simulating IUs randomly
distributing to the M cells, averaged over 1000 iterations. (b) The analytical result obtained from Eq. 2. (c) The asymptotic approximation
withM = 10 and µ = N
M
= 10, using the expression in Eq. 6. There is close agreement between the simulated and analytical results. The
relatively low values ofM and N makes the asymptotic formula in Eq. 6 inappropriate for this parameter regime, explaining the discrepancy
between the asymptotic result and the exact analytical result. However, it is noteworthy how qualitatively small that deviation is, which will
continue to vanish asM and N increase in value.
FIG. 4: The probability of observing a cytopathic effect (CE) given
in Eq. 12 as a function of the dilution number d and with Q = 1.
(a) For D = 10, as the initial particle count N0 increases, the crit-
ical dilution moves toward higher d. (b) Common dilution factors
include logarithmic dilution (D = 10), half-logarithmic dilution
(D = 101/2), and quarter-logarithmic dilution (D = 101/4). Log-
arithmic dilution requires a lower number of dilutions to cause the
characteristic decrease in probability, requiring less individual assays
to perform. Quarter-logarithmic dilution, though requiring more di-
lutions, has a slower transition from high to low probability across d,
making the assay less sensitive to experimental error or noise. The
plot above can be used to quantify the tradeoffs between the choices
of D.
surface. After a sufficient critical dilution number dc however,
the number of plaques formed are low enough to be visibly
distinct and countable. For each dilution number d, the assay
can be performed for T number of trials. The ‘signal’ data
arising from the plaque assay Pd,t is defined as the number
of visible plaques counted, where t = 1, · · · , T is the trial
number. The standard method of obtaining an estimate Nˆ0 of
the true particle count N0 is to apply the sample mean of the
data Pdc,t at the critical dilution level dc to the formula
Nˆ0 = D
dc
(
1
T
T∑
t=1
Pdc,t
)
, (13)
which posits that the average number of plaques is directly
proportional to the particle count N0. Eq. 13 assumes that
each infected cell corresponds to one IU, which is not neces-
sarily true in the context of SMOI. Furthermore, although data
corresponding to dilution numbers d < dc are unusable, data
for d > dc corresponding to countable plaques are not used at
all in Eq. 13.
In order to improve on Eq. 13 by using the entire set of
plaque counts Pd,t for our estimate ofN0, we propose a max-
imum likelihood estimation (MLE) scheme. Using the math-
ematical models derived above, we can construct an expres-
sion L(Pd,t|N0) of the probability that the observed data Pd,t
can be generated assuming a particular value for N0, known
as a likelihood function. A value for N0 that maximizes
L(Pd,t|N0) corresponds to the most probable estimate Nˆ0 that
could have generated the data. As each nucleation of a plaque
corresponds to a distinct infected cell (and assuming that over-
lapping lesions of necrotic cells are still discernible as distinct
plaques), we can equate Pd,t to the total number of success-
fully infected cellsM∗. We will ignore the dynamics of coin-
fection and viral interference. Using Eq. 9, we propose the
following likelihood function of the data givenN0:
L(Pd,t|N0) =
dmax∏
d=dc
T∏
t=1
(
M
Pd,t
)[
1− exp
(
−
N0
QMDd
)]Pd,t
exp
(
−
N0
QMDd
)M−Pd,t
. (14)
To obtain the MLE Nˆ0, we take the derivative of the natural log of Eq. 14 with respect to N0 and set the result to zero to
6Plaque Count Data from Sloutskin et al [36].
Trial 10−2 10−3 10−4 10−5 10−6 10−7
1 – – 111 24 1 0
2 – – 126 24 1 0
3 – – 121 13 0 0
FIG. 5: An example of raw plaque count data taken from Sloutskin
et al. [36]. A viral solution was assayed in a plate ofM = 3 × 105
cells at dilution numbers d = 2, 3, 4, 5, 6, and 7 at a dilution factor
of D = 10. The particle to PFU ratio is assumed to be Q = 1.
For T = 3 separate trials, the number of plaques were counted at
each dilution level. The bottom row of plates used as a control is
ignored. For dilution numbers d = 2 and 3, the entire plate of cells
show cytotoxicity so that the numbers of plaques were undiscernable
and, thus, the countable data starts at dc = 4. For the old method
featured in Eq. 13, the estimate for N0 is Nˆ0 = 1.19 × 10
6 and
for the MLE derived from Eq. 15, Nˆ0 = 1.26 × 10
6. This results
in a relative difference of 5.5%. Furthermore, when applying these
parameters and Nˆ0 estimate to Eq. 17, we observe a 10.7% decrease
in the estimate variation using the MLE technique.
obtain
0 =
dmax∑
d=dc
T∑
t=1
M exp
(
− Nˆ0
QMDd
)
−M + Pd,t
QMDd
[
1− exp
(
− Nˆ0
QMDd
)] . (15)
We can solve Eq. 15 for Nˆ0 using numerical methods such
as Newton-Raphson [37], an iterative scheme that approaches
the solution of an equation asymptotically starting from an
initial guess Nˆ init0 . To increase the stability of convergence
to the solution, we choose Nˆ init0 by equating the sample av-
erage of plaque counts 1
T
∑
Pdc,t with the expected number
of infected cells E[M∗] in Eq. 10 at the critical dilution dc to
derive
Nˆ init0 = −QMD
dc ln
[
1−
1
M
(
1
T
T∑
t=1
Pdc,t
)]
. (16)
An example of raw plaque count data and the resulting esti-
mates forN0 are given in Fig. 5. In order to quantify the rela-
tive improvement of the MLE ofN0 over the standard method
in Eq. 13, we simulate plaque assay data assuming a fixed,
known N0 value. In our simulation, we use the models es-
tablished in Section II A to sample the N0 particles according
to Eq. (S9) in Appendix A to account for serial dilution and
FIG. 6: Results of plaque assay simulation for parametersN0 = 10
6,
M = 105, Q = 1, D = 10, dmax = 10, and T = 10. (a) The
scatter plot of simulated data Pd,t (circles) and the expected value
of plaque counts as given by Eq. 10 show close agreement. (b) The
likelihood function L(Pd,t|N0) with respect to N0 using the same
simulated data. The MLE obtained by iteratively solving Eq. 15 is
Nˆ0 = 9.97×10
5 and is relatively closer to the true value ofN0 than
the estimate calculated from the standard method in Eq. 13 Nˆ0 =
1.02× 106.
sample again the resulting particles according to Eq. 1 to ob-
tain the number of IUs N . The IUs are distributed randomly
to theM cells with equal probability and the resulting number
of infected cellsM∗ is recorded. Since plates of cells with too
many infections render the number of plaques uncountable, a
“countable plaque threshold” renders the data unusable when
the number of infected cells exceed the threshold. Thus, the
resulting plaque data Pd,t for a given dilution d and trial t
is assigned the number of simulated infected cells if the lat-
ter is less than the given threshold. A scatter plot of the data
Pd,t of one such simulation is shown in Fig. 6a and the corre-
sponding likelihood function from Eq. 14 is plotted in Fig. 6b.
Because the MLE method utilizes a full probabilistic model
of the plaque count distribution instead of relying only on the
expected value at the single critical dilution dc, it produces an
estimate consistently closer to the original N0 that generated
the data. To better quantify this property, in Appendix E we
derive an asymptotic approximation of the variance of Nˆ0 as
Var
[
Nˆ0
]
≈

dmax∑
d=dc
T exp
(
− N0
QMDd
)
Q2MD2d
[
1− exp
(
− N0
QMDd
)]


−1
.
(17)
The variance is an explicit function of Q, which is assumed
to be a priori known. If there is uncertainty in the value of
Q, Eq. 17 can quantify how sensitive the distribution of Nˆ0
is to variation in Q, as shown in Fig. 7a. We can see that
for small assumed Q, such as in poliovirus [31], error in this
measurement can cause a large relative change in the accuracy
of Nˆ0. This type of sensitivity analysis on estimation vari-
ance can be done with any experimental parameter included
in the likelihood function in Eq. 14. Furthermore, for directly
controllable parameters, such as the serial dilution factor D,
Eq. 17 can provide insight into optimizing the assay proto-
col, as shown in Fig. 7b. Although it is evident that small
D would increase the accuracy of the Nˆ0 estimate, doing so
requires more serial dilutions which increases the time and ex-
pense of the assay. Thus, our sensitivity analysis provides a
7FIG. 7: Approximations of the standard deviation σNˆ0 =
Var[Nˆ0]
1/2 of maximum likelihood estimates for the plaque assay
using Eq. 17 and parameters Nˆ0 = 10
5, 106, and 107,M = 3×105,
dc = 4, dmax = 7, and T = 3, corresponding to the assay displayed
in Figure 5. (a) For D = 10, the standard deviation increases pro-
portional to the square root of Q. (b) For Q = 1, we can see a low
dilution factor D will increase the accuracy of the estimate Nˆ0.
quantitative method for making experimental design choices
between minimizing uncertainty versus the cost of an assay
protocol. Lastly, if we compute the variance of the standard
method in Eq. 13 due to the known variance in the data Pd,t,
and compare with Eq. 17, we find, when using realistic pa-
rameter values from Fig. 5, the standard method results in a
10.7% higher variance than that of our method. Although the
significance of the relative increase in precision of estimating
N0 found using our method is highly dependent on the context
of the experimental study for which the assay was performed,
similar sensitivity analysis can be used to determine such tol-
erances.
B. Endpoint Dilution Assay
Another widely used assay for quantifying the initial viral
particle countN0 is the endpoint dilution or endpoint titration
assay [23, 25, 38]. It is often used in place of the plaque assay
as it can be more rapidly performed and is useful for viral
strains that are unable to form plaques. Here, serial dilutions
at a factor of D are employed and at every dilution number
d, an assay is performed T times to test for a successful CE.
The numberEd of observed CEs among the T trials at a given
dilution number d is recorded as the signal. For low dilution,
we expect many cells to be infected and the probability of
observing a CE, as shown in Eq. 12, is close to 1. If every trial
of the assay is likely to display a CE, thenEd is expected to be
close to T . However, at high dilution, the probability in Eq. 12
rapidly decreases to 0, as shown in Fig. 4, and Ed will be
similarly small. For a large initial stock of viral particles N0,
a larger dilution number d is needed to ensure the dramatic
change in probability in Eq. 12. Thus, the critical dilution
at which Ed most rapidly decreases from T can be used to
estimate the particle count N0. This occurs at the point of
inflection when d = logD(N0Q
−1) and corresponds to when
the expected number of successful trials E[Ed] = T (1−e
−1),
as shown in Fig. 8.
One commonly used way to estimate N0 is the Reed and
Muench (RM) method that utilizes the two dilution numbers
that capture the greatest change in the data Ed [28]. We first
define a critical dilution number d50% to be the largest dilution
such that at least 50% of the trials exhibit a CE. The estimate
Nˆ0 for the particle countN0 is given by
log10(Nˆ0) = d50% +
Ed50% − 0.5T
Ed50% − Ed50%+1
. (18)
The RM method effectively attempts to approximate the
steepest descent of the CE probability given in Eq. 12 with
a line connecting the assay data at dilutions d50% and d50%+1,
as displayed in Fig. 8a. Unfortunately, this line always rests
above the actual expectation curve of Ed, so any estimate
Nˆ0 obtained from this method will overestimate the true N0.
Another commonly used estimation scheme is the Spearman-
Karber (SK) method which uses the critical dilution number
d100%, the largest dilution such that 100% of trials exhibit a
cytopathic effect [29, 38]. The SK estimate Nˆ0 is given by
log10(Nˆ0) = d100% −
1
2
log10(D) + log10(D)
dmax∑
d=d100%
Ed
T
.
(19)
In this method, the downward slope for the expectation of Ed
is assumed to follow a decaying exponential starting at di-
lution d100%, as shown in Fig. 8b. The intention is to find
the dilution at which Te−1 CEs are expected by calculating
the area under the exponential curve, given by the summa-
tion term in Eq. 19. However, the actual values of Ed will
follow the expected curve from our model, leading to an over-
estimate of the area and, by extension, a larger value for Nˆ0.
Both standard methods were derived from the heuristic obser-
vation thatEd exhibits sigmoidal behavior as a function of the
dilution number d, but an underlying probabilistic model was
missing, resulting in consistent overestimation of the trueN0.
Furthermore, neither method uses the “particle to PFU ratio”
Q, accounts for the stochasticity of serial diluting viral sam-
ples, considers the dynamics of SMOI, or employs the entire
set of data Ed.
We present an alternative way to infer N0 using Eq. 12 to
establish a maximum likelihood estimation scheme. We re-
strict ourselves to in vitro assays in which a single infected
cell is sufficient to display a CE. Then each cytopathic count is
binomially distributed with parameters T and the probability
given in Eq. 12. Thus, for a set of data {E1, E2, · · · , Edmax},
we propose the likelihood function
L(Ed|N0) =
dmax∏
d=1
(
T
Ed
)[
e
N0
QDd − 1
]Ed
e
−
TN0
QDd . (20)
Eq. 20 is an expression of the probability of the data
{E1, · · · , Edmax} given the current assumed value of N0. To
obtain the best estimate Nˆ0 of N0, we maximize the likeli-
hood function by taking the log and derivative of L(Ed|N0)
with respect to N0 and set it equal to zero to obtain
0 =
dmax∑
d=1
Ed − T + T exp
(
− Nˆ0
QDd
)
QDd
(
1− exp
(
− Nˆ0
QDd
)) . (21)
8FIG. 8: An illustration of the consistent overestimation of the Reed
and Muench (RM) and Spearman-Karber (SK) methods using the ex-
pected curve E[Ed] of CEs given T trials as a function of the dilution
number d derived from Eq. 12. (a) The RM method approximates
the steepest decent of the expectation curve with a line connecting
the two data points Ed50% ≤ 0.5T < Ed50%+1. Because of the
relative convexity of the expected curve, the linear approximation
consistently rests above the curve and results in an overestimate of
log10(Nˆ0). (b) From the last dilution d100% such that all trials ex-
hibit a CE, the SK method assumes an exponential decay of the ex-
pectation. Obtaining the characteristic decay rate of the exponential
involves calculating the area under the curve, which is done numeri-
cally using the data Ed. However, according to our model, many of
the expected values of Ed exist above the exponential, causing the
numerical integration to overestimate the area and, thus, decay too
slowly. This gradual decrease in the exponential curve results in a
larger estimate of log10(Nˆ0).
As with Eq. 15, solving Eq. 21 for Nˆ0 requires a numerical
method such as Newton-Raphson. As an appropriate initial
estimate for Nˆ0, the formula
Nˆ init0 = −0.5QD
dc
[
ln
(
1−
Edc
T
)
+D ln
(
1−
Edc+1
T
)]
,
(22)
can be used, where dc is the largest dilution number such that
at least half of the trials exhibit a cytopathic effect. Eq. 22 is
the average of theN0 estimates at dilutions dc and dc+1 when
setting the CE probability in Eq. 12 to 1/2. For a comparison
of our MLE method with the RM and SK methods, we sim-
ulate data similar to that described in Section IIIA. Here we
take the number of trials such that the simulated count of in-
fected cells is greater than zero as the values of Ed for a given
dilution number d. We plot the likelihood from Eq. 20 and
compare the MLE of N0 with those derived by the RM and
SK methods in Fig. 9a. While both RM and SK estimate very
similar values of Nˆ0, they both consistently over-estimate the
a priori setN0 relative to theMLEmethod. This demonstrates
the advantage of a probabilistic model for parameter inference
over heuristically determined formulas.
The expressions we derived in Eqs. 14 and 20 applied to
simulated data can also help quantify tradeoffs in experimen-
tal design. As discussed above, there exist viruses that can-
not form plaques, restricting the options of VQAs to end-
point dilution. However, for many cases, the choice between
using one assay over the other can be one of convenience.
More specifically, endpoint dilution assays can often be per-
formed more rapidly than plaque assays. Using the same
simulated data for both assays, we plot Eqs. 14 and 20 to-
FIG. 9: (a) The likelihood function L(Ed|N0) in Eq. 20 for the
endpoint dilution assay and the corresponding maximum likelihood,
Reed and Muench, and Spearman-Karber estimates given simulated
data generated with N0 = 10
6, Q = 1, D = 10, and dmax = 10.
The estimates for maximum likelihood (Nˆ0 = 1.33 × 10
6), RM
(Nˆ0 = 2.51 × 10
6), and SK (Nˆ0 = 2.51 × 10
6) all overestimate
N0, but the smaller relative error of the MLE is an improvement on
the errors of the existing two methods. (b) The likelihood functions
L(Pd,t|N0) and L(Ed|N0) for the plaque and endpoint dilution as-
says respectively given simulated data. The data was generated with
parameters N0 = 10
6,M = 105, Q = 1, D = 101/4, dmax = 30,
and a “countable plaque threshold” of 150. The plaque assay like-
lihood is concentrated close to the true N0 value while the endpoint
dilution likelihood is far more spread out and overestimatesN0. This
direct quantitative comparison can inform an experimentalist when
choosing between the two methods.
gether in Fig. 9b. The plots clearly show the superiority of the
plaque assay for estimating the viral stock number N0 in re-
spect to both how close the MLE infers the true N0 value and
the amount of variance in that estimate. While the amount of
variability and error that is tolerable for an experiment may be
context-dependent, the plots in Fig. 9b provide a quantitative
way to differentiate between the two methods.
C. Luciferase Reporter Assay
The luciferase reporter assay is commonly used to measure
the infectivity of a viral strain. Here the ratio µ = N/M of
total infections over the number of plated cells is estimated by
measuring the transcription activity of viral proteins [14–16].
The reporter employs an oxidative enzyme luciferase that fa-
cilitates a reaction when introduced to the substrate luciferin,
resulting in bioluminescence. The protocol begins with at-
taching the luciferase gene to the viral genome. The altered
viral strain is cloned to a total particle count N0 which, in
this case, is assumed to be fixed and known. The solution
of viruses is added to a plated monolayer of M host cells.
An incubation time is allowed for transcription of viral pro-
teins and, incidentally, the luciferase enzyme. Subsequently
all cells are lysed to release all cytoplasmic contents into the
solution upon which luciferin is added. The oxidation of lu-
ciferin is facilitated by the luciferase enzyme and the resulting
bioluminescence yields a measurable signal [39]. The light in-
tensity is thus a measure of total transcription activity of the
viral genome in all infected cells and can be used as a proxy
for the total number of viruses N that successfully infected
9Although there is stochasticity in transcription factor bind-
ing and, in the case of retroviruses, the number of integra-
tion sites on the host DNA, we will assume that each success-
ful virus infection contributes one viral genome to be tran-
scribed and each transcription occurs at a constant rate pro-
portional to the total number of integrated viral genomes.
Note that the limited number of transcription factors, ribo-
somes, and other cell machinery necessary to produce viral
proteins and the luciferase reporter causes the production rate
to saturate as the number of infecting viruses r per cell in-
creases. Thus, transcription activity saturates with increasing
number of infections r. We can model this effect by defin-
ing a monotonically increasing function f(r) representing the
number of transcribed viral proteins when a cell is infected by
r viruses over the course of the assay. Thus, for a given SMOI
{M0, · · · ,MN}, we will model the intensity signal L of the
total luciferase reporter luminescence with
L =
N∑
r=0
L0f(r)Mr , (23)
where L0 is the fluorescence intensity arising from a single
luciferase reporter present in the solution. Although f(r)may
take on many functional forms, a commonly used model for
transcription factor kinetics is the Hill function [40] given by
f(r) =
fmaxr
h
K + rh
, (24)
where fmax is the maximum transcription activity of lu-
ciferase, h is the Hill coefficient that effectively describes co-
operative binding of multiple transcription factors at a pro-
moter region, and K is an effective dissociation constant re-
lating the binding and unbinding rates of transcription factor.
The functional form of Eq. 24 accounts for the limited tran-
scription machinery available for the multiple copies of vi-
ral genome present in the cell. In Fig. 10a we calculate the
discrete probability distribution Pr(L = ℓ) by considering
the cumulative weight of every allowable configuration of N
viruses infectingM cells through Eq. 23.
Since luciferase reporter assays typically involve large val-
ues of initial virus count N0 and cell count M , we can use
the asymptotic approximations in Eqs. 6 and 7 along with
the Central Limit Theorem [41] to assume L is normally dis-
tributed with expected value
E[L] = L0fmaxMe
−µ
N∑
r=0
rhµr
(K + rh)r!
, (25)
and variance
Var[L] = L20f
2
maxMe
−µ
N∑
r=0
r2hµr
(K + rh)2r!
. (26)
A visualization of the normal approximation of the proba-
bility distribution of L is shown in Fig. 10b. Furthermore,
with Eqs. 25 and 26, we can derive the likelihood function
FIG. 10: Probability distributions of the luciferase assay fluorescence
intensity L from Eq. 23. (a) A toy example of a discrete probability
distribution of allowable fluorescence intensities forN = 30 viruses
infectingM = 20 cells. Due to theMN finite number of allowable
configurations of the SMOI, there are a corresponding finite num-
ber of intensities with specific probabilities determined by Eq. 5 and
represented by a unique circle. The parameters used for the reporter
kinetics are fmax = 2, h = 1, K = 1 and L0 = 1. The mean in-
tensity of the fluorescence signal is E[L] = 19.5, represented by the
vertical dotted line, and variance Var[L] = 1.49, represented by the
shaded region. (b) The normally distributed approximation of fluo-
rescence intensity using M = 105, fmax = 2, h = 1, K = 1 and
L0 = 1. The distributions are plotted for µ = 1.4, 1.5, and 1.6 by
computing the expected values E[L] = 9.23× 104, 9.64× 104, and
105 and the variancesVar[L] = 1.7×105 , 1.24×105 , and 1.3×105
respectively.
L(Ldatat |µ) of the data L
data
t , given µ
L(Ldatat |µ) =
T∏
t=0
1√
2πVar[L]
exp
[
−
(
Ldatat − E[L]
)2
2Var[L]
]
,
(27)
where 1 ≤ t ≤ T is the trial number. Due to the complicated
functional form of the mean and variance of L, creating a
maximum likelihood scheme to estimate µ from experimental
data is intractable, so we use Eq. 25 by replacing the expected
value with the experimental average of measurements Ldatat .
If we assume no cooperative transcription binding (h = 1),
we solve for the estimate µˆ by applying the Newton-Raphson
iterative method to the equation
0 =
1
T
T∑
t=0
Ldatat − L0fmaxMe
−µˆ
N0∑
r=0
rµˆr
(K + r)r!
. (28)
The typical method, under the assumption that luminescent
intensity is proportional to the number of IUs N , is to use
the sample mean via the formula µˆinit = 1
L0MT
∑T
t=0 L
data
t .
This standard approach fails to account for the effects of
SMOI, but can be used to generate an initial guess for solv-
ing Eq. 28 iteratively. In order to compare the two estimates,
we simulate data similar the descriptions in the previous two
sections. Here, we do not dilute the initial particle count and,
after distributing the N IUs to the M cells with equal proba-
bility, we compile the SMOI configuration and calculateLdatat
using Eq. 23. The results are shown in Fig. 11. The iterative
method produces an estimate µˆ far closer to the true value of
µ than the former method. A similar approach can be used to
compare methods for alternative functional forms of the viral
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FIG. 11: The likelihood function L(Ldatat |µ) using Eq. 27 and sim-
ulated data. We set µ = 1.5 and assign other parameters with
M = 105, fmax = 2, h = 1, K = 1 and L0 = 1. The esti-
mate derived from solving Eq. 28 is µˆ = 1.502 while the standard
method based on the sample mean yields µˆ = 0.97, far lower than
what is displayed in the plot.
protein transcription dynamics described in Eq. 24.
IV. CONCLUSION
In this work, we derived probability models that quantify
the viral infectivity of host cells in an in vitro environment.
By factoring in the stochastic nature of virus-host engage-
ment, defective and/or abortive events, and the possibility of
multiple infections of a single host, we defined the statistical
multiplicity of infection (SMOI) and determined related prob-
abilistic models. We analyzed two limiting regimes: small
numbers of infecting viruses N and large N . For the low N
regime, Eqs. 2 and 5 model how the limited number of infec-
tious units are distributed amongst theM host cells. Alterna-
tively, for large N , we showed the cell counts of the SMOI
become statistically independent, as displayed in Eq. 8, and
that they display a Poisson distribution (Eq. 6). Lastly, we
explored the effects of serial dilution on the total number of
infected cells and the probability of observing an infectious
signal in Eq. 9.
Using our probability models along with reasonable as-
sumptions of applied combinatorics and nonlinear inference,
we analytically derived expressions for several virus assays
to improve on existing methods of experimental data analy-
sis. For virus quantification assays, serial dilution results in
low numbers of viral particles. Using the appropriate proba-
bility model, we created new methods of estimating the par-
ticle count N0 in the initial viral stock for the plaque assay
and the endpoint dilution assay. For measuring infectivity of
a viral strain, the objective is to determine the effective mul-
tiplicity of infection µ = N/M as the ratio of successfully
infecting viruses N and the total number of cellsM included
in the assay. As these assays operate under no dilution, we
employed the large N limit probability model to analytically
derive expressions for the luciferase reporter assay to estimate
µ. A summary of each estimation method along with the most
commonly used counterpart is displayed in Table I.
VQAs are primarily concerned with inferring N0 and as-
sume a priori knowledge of M and the particle to PFU ra-
tio Q. In actuality, there can be variability in the number of
cells present in the microtiter well and, as discussed in Sec-
tion IIA, the true value of Q is dependent on the particu-
lar protocol and particular conditions under which an assay
was performed. If an alternative assay (RNA tagging, spec-
troscopy, super-resolution imaging, etc.) not using cell infec-
tion can accurately measure N0, then, in theory, a subsequent
infection assay can be used to infer a more reliable measure
of Q. In fact, in our analysis of the plaque assay presented
in Appendix E of the SI, we show that one can determine a
significantly higher amount of information about Q with the
same assay protocol if N0 is a priori known, rather than the
reverse case. Thus, one may argue that assays that employ
serial dilution, such as plaque and endpoint dilution assays,
may be better utilized to inferQ. Because the underlying like-
lihood of the data in all assays would be the same, the same
derivation techniques would follow with respect to Q in order
to formulate its maximum likelihood estimate. This analysis
shows the robust utility of a full probabilistic model and data
likelihood function.
Although the derived assay models provide explicit equa-
tions for inference, many of the expressions are analytically
unsolvable and require numerical solutions. To improve the
accessibility of some of our results, we have created a web-
based tool (available at https://bamistry.github.io/SMOI/) that
can accept data from either plaque, endpoint dilution, or lu-
ciferase reporter assays and automatically estimate the param-
eter of interest. Ultimately, these tools can be used for analy-
sis of future virological studies, but may also be useful when
revisiting results of studies that stress quantifying viral infec-
tivity [15, 42]. For studies that use serial dilution assays, our
approach stresses the advantages of using information in the
data associated with all dilution numbers rather than just that
of the critical dilution.
Our probabilistic models of viral infection can be further
generalized to include, for example, the effects of cell size in-
homogeneity, coinfection, and viral interference. In the Sup-
plemental Information, we provide a framework that would
allow one to explore how these confounding factors can fur-
ther alter the signal of a virus assay. Future refinement of these
extensions can help to ultimately derive a mechanistic model
for the probability of a single virus successfully infecting a
host cell, which we defined as Q−1. Understanding this prob-
ability of infection can help aid further experimental design
and allow better quantification and resolution of the infection
dynamics of particular viral strains.
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TABLE I: A summary of the analytically derived expressions used to analyze experimental results. For virus quantification assays, such as the
plaque and endpoint dilution assays, one typically wishes to estimate the number of initial viral particlesN0. For luciferase reporter infectivity
assay, the ratio µ = N/M is desired. Our improved parameter estimation methods are listed next to standard methods currently used.
Comparison of Virological Assay Analyses
Assay
(Parameter)
Standard Method New Method
Plaque
(N0)
Nˆ0 = D
dc
(
1
T
T∑
t=1
Pdc,t
) 0 = dmax∑
d=dc
T∑
t=1
M exp
(
− Nˆ0
QMDd
)
−M + Pd,t
QMDd
[
1− exp
(
− Nˆ0
QMDd
)]
Initial guess:
Nˆ init0 = −QMD
d ln
(
1−
1
MT
T∑
t=1
Pdc,t
)
Endpoint
Dilution
(N0)
Reed and Muench:
log10(Nˆ0) = d50% +
Ed50% − 0.5T
Ed50% − Ed50%+1
Spearman-Karber:
log10(Nˆ0) = d100% −

1
2
−
dmax∑
d=d100%
Ed
T

 log10D
0 =
dmax∑
d=1
Ed − T + T exp
(
− Nˆ0
QDd
)
QDd
(
1− exp
(
− Nˆ0
QDd
))
Initial guess:
Nˆ init0 =
−QDdc
2
ln
[(
1−
Edc
T
)(
1−
Edc+1
T
)D]
Luciferase
Reporter(
µ = N
M
) µˆ = 1
L0MT
T∑
t=0
Ldatat
0 =
1
T
T∑
t=0
Ldatat − L0fmaxMe
−µˆ
N0∑
r=0
rµˆr
(K + r)r!
Initial guess:
µˆinit =
1
L0MT
T∑
t=0
Ldatat
research.
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Supplementary Information
Appendix A: Mathematical Appendices
SMOI Probability
To derive Eq. 2, we index all cells with i ∈ {1, · · · ,M} and define Ari as the event that cell i is infected by exactly r IUs.
Then, givenN IUs across allM cells, the probability of Ari is given by
Pr(Ari |M,N) =
(
N
r
)(
1
M
)r (
1−
1
M
)N−r
. (S1)
Since cell sizes are assumed to be homogeneous, the probability in Eq. S1 is the same for all cells, but the events {Ar1, · · · , A
r
M}
are not independent as the number of IUs N shared among theM cells is finite. Thus, we use the inclusion-exclusion principle
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[41] to derive
Pr(Mr = mr|M,N) =
M∑
j=mr
(−1)j−mr
(
j
mr
) ∑
I⊂{1,··· ,M}
|I|=j
Pr
(⋂
i∈I
Ari
)
=
M∑
j=mr
(−1)j−mr
(
j
mr
)(
M
j
)
Pr
(
j⋂
i=1
Ari
)
=
M∑
j=mr
(−1)j−mr
(
j
mr
)(
M
j
)(
N
r, · · · , r, (N − rj)
)[ j∏
i=1
(
1
M
)r](
M − j
M
)N−rj
=
M∑
j=mr
(
j
mr
)(
M
j
)(
N
r, · · · , r, (N − rj)
)
(−1)j−mr (M − j)
N−rj
MN
. (S2)
Note that the inner summation in the first identity above is over every possible collection of cells of size j, but as each cell is
identical, the sum can be reduced to a single joint probability with the binomial degeneracy
(
M
j
)
.
Expected Value and Variance
For the generalized c-th moment E [M cr ] of the number of cellsMr infected by exactly r viruses, we start with Eq. 2 to obtain
E [M cr ] =
M∑
mr=0
M∑
j=mr
mcr(−1)
j−mr
(
j
mr
)(
M
j
)(
N !
(r!)
j
(N − rj)!
)
(M − j)
N−rj
MN
=
M∑
j=0
[
j∑
mr=0
mcr(−1)
j−mr
(
j
mr
)](
M
j
)(
N !
(r!)j (N − rj)!
)
(M − j)
N−rj
MN
(S3)
To aid our derivation, we define the function u(j, c) as
u(j, c) =
j∑
m=0
mc(−1)j−m
(
j
m
)
= j
j−1∑
k=0
(k + 1)c−1(−1)j−1−k
(
j − 1
k
)
= j
c−1∑
i=0
(
c− 1
i
) j−1∑
k=0
ki(−1)j−1−k
(
j − 1
k
)
= j
c−1∑
i=0
(
c− 1
i
)
u(j − 1, i). (S4)
This is a recursive relationship from which we can evaluate any u(j, c) using all u(j− 1, i) such that 0 ≤ i < c. We evaluate the
first three cases u(j, 0) = δ0,j , u(j, 1) = δ1,j , and u(j, 2) = δ1,j + 2δ2,j , where δ0,j is the Kronecker delta operator that returns
the value 1 when the two subscript arguments are equal and 0 otherwise. We use the result for c = 1 and Eq. S3 to calculate the
expected value ofMr as
E [Mr] =
M∑
j=0
δ1,j
(
M
j
)(
N !
(r!)
j
(N − rj)!
)
(M − j)
N−rj
MN
= M
(
N
r
)(
1
M
)r (
1−
1
M
)N−r
. (S5)
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We obtain the second moment E
[
M2r
]
using the same method in order to obtain the variance ofMr as
Var [Mr] = E
[
M2r
]
− E [Mr]
2
= M
(
N
r
)(
1
M
)r (
1−
1
M
)N−r
+
M(M − 1)N !(M − 2)N−2r
(r!)2(N − 2r)!MN
−
M2(N !)2(M − 1)2N−2r
(r!)2 [(N − r)!]
2
M2N
. (S6)
Asymptotic Approximation
For the derivation of Eq. 6, we take the mathematical limitN,M →∞ while keeping the ratio µ = N
M
fixed and approximate
Eq. 2 as follows:
Pr(Mr = mr|M,N) =
M∑
j=mr
j!M !N !(−1)j−mr (M − j)N−rj
mr!(j −mr)!j!(M − j)!(N − rj)!(r!)jMN−rjM rj
=
1
mr!
M∑
j=mr
(−1)j−mr
(j −mr)!(r!)j
[M · · · (M − j + 1)]
[N · · · (N − rj + 1)]
M rj
(
1−
j
M
)N−rj
≈
1
mr!
M∑
j=mr
(−1)j−mr
(j −mr)!(r!)j
M jµjre−µj
≈
1
mr!
[
Mµre−µ
r!
]mr
exp
[
−
Mµre−µ
r!
]
. (S7)
Note that, although the first approximation requires j in the summation to be sufficiently smaller than M , any contribution
from the summation for j close toM vanishes due to both the (j −mr)! term in the denominator and the
(
1− j
M
)N−rj
term
approaching 0. Under the same largeM,N limit, we can derive an asymptotic approximation of the joint probability distribution
by taking the natural log of both sides of Eq. 5:
ln Pr(M0 = m0, · · · ,MN = mN ) = ln
(
1
MN
)
+ lnM ! + lnN ! +
N∑
r=0
ln
(
1
mr!(r!)mr
)
≈ −N lnM +M ln(M)−M +N ln(N)−N +
N∑
r=0
ln
(
1
mr!(r!)mr
)
= lnµ
(
N∑
r=0
rmr
)
+ (lnM − µ)
(
N∑
r=0
mr
)
−Me−µ
(
∞∑
r=0
µr
r!
)
+
N∑
r=0
ln
(
1
mr!(r!)mr
)
=
N∑
r=0
ln
[
µrmrMmre−mrµ
mr!(r!)mr
exp
(
−
Me−µµr
r!
)]
−O
(
MµN
N !
)
≈ ln
[
N∏
r=0
1
mr!
[
Mµre−µ
r!
]mr
exp
(
−
Mµre−µ
r!
)]
. (S8)
Since the argument in the right-hand-side of the last approximation is the same as Eq. 6, we arrive at the result in Eq. 8.
Number of Infected Cells
To derive Eq. 9, we first define Nd as the number of virus particles present in the viral solution after dilution of a factor of
Dd. ObtainingNd is effectively analogous to taking a volume of the initial viral stock scaled by D
−d and counting the number
of particles captured in the volume. Thus, we expect Nd to be Poisson-distributed with mean N0D
−d and discrete probability
14
density function given by
Pr (Nd = nd|N0) =
1
nd!
(
N0
Dd
)nd
exp
(
−
N0
Dd
)
. (S9)
OnceNd is chosen from the above distribution, for a given “particle to PFU ratio”Q, the number of IUsN follows a binomial dis-
tribution with a probability function similar to Eq. 1, but withN0 replaced withNd. Note that, given an SMOI {M0, · · · ,MN},
it is immediate thatM∗ =M −M0. Using this modified density ofN and Eqs. 2 and S9, we can derive the discrete probability
density function ofM∗ at a given dilution number d as
Pr (M∗ = m) =
N0∑
nd=0
nd∑
n=0
Pr(N = n|Nd = nd)Pr(M0 =M −m|N = n)Pr(Nd = nd)
=
M∑
j=M−m
(−1)j−M+m
(
j
M −m
)(
M
j
)
e−
N0
Dd
N0∑
nd=0
(
N0
Dd
)nd
nd!
[
1−Q−1 +Q−1
(
1−
j
M
)]nd
≈
M∑
j=M−m
(−1)j−M+m
(
j
M −m
)(
M
j
)
exp
[
N0
Dd
(
1−
j
QM
)
−
N0
Dd
]
=
(
M
m
)[
1− exp
(
−
N0
QMDd
)]m
exp
(
−
N0
QMDd
)M−m
. (S10)
Note that the approximation that closes the exponential term in the final result employs the assumption that N0 is sufficiently
large.
Appendix B: Inhomogeneous Cell Size
We derived the probability distribution in Eq. 2 assuming the plated host cells are of identical size and volume. This may
not necessarily be the case as each cell exists at different stages of the mitotic cycle, will attach to the plate bottom at random
locations, and contain deformities in shape and size. Assuming cells cover the entire surface of the well bottom, Pineda et al.
[43] showed that the cell size proportion pi for cell i is gamma distributed with probability density
f(pi) =
Mνννpν−1i exp(−νMpi)
Γ(ν)
, (S1)
where ν is a parameter that can be estimated, for example, by fitting imaging data of cells. Under a specific realization of cell
size distributions {p1, · · · , pM}, we define A
r
i as the event that cell i is infected by exactly r viruses with probability
Pr(Ari ) =
(
N
r
)
pri (1− pi)
N−r. (S2)
Using the inclusion-exclusion principle as above, we derive the conditional probability distribution of the number of cells Mr
that were infected by exactly r viruses as
Pr(Mr = mr|p1, · · · , pM ) =
M∑
j=mr
(−1)j−mr
(
j
mr
) ∑
|{iw}|=j
Pr
(
j⋂
w=1
Ariw
)
=
M∑
j=mr
(−1)j−mr
(
j
mr
) ∑
|{iw}|=j
(
N
r, · · · , r, (N − rj)
)
pri1 · · · p
r
ij
(
1−
j∑
w=1
piw
)N−rj
=
M∑
j=mr
(−1)j−mr
(
j
mr
) ∑
|{iw}|=j
N !
(r!)j(N − rj)!
(
j∏
w=1
piw
)r (
1−
j∑
w=1
piw
)N−rj
. (S3)
In order to obtain the full probability, we first take note that each cell size proportion pi is dependent on each other as they are
constrained by
∑M
i pi = 1. We avoid this dependency by noticing the expression in Eq. S1 approaches zero very rapidly as pi
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moves away from the expected value 1/M . If we define a sufficiently large proportion pˆ such that the interval [0, pˆ] contains the
majority of the area under the probability density in Eq. S1, we can make the approximation
Pr(Mr = mr) =
∫ 1
0
· · ·
∫ 1
0
Pr(Mr = mr|p1, · · · , pM )f(p1, · · · , pM )dp1 · · · dpM
≈
[
Mνννe−ν
Γ(ν)
]M ∫ pˆ
0
· · ·
∫ pˆ
0
Pr(Mr = mr|p1, · · · , pM )
(
M∏
w=1
pw
)ν−1
dp1 · · · dpM . (S4)
It is clear that introducing cell size inhomogeneity dramatically increases the complexity of our probabilistic SMOI model.
For relatively small numbers of cellsM , image processing can be used to determine an estimation of a particular realization of
cell size distribution {p1, · · · , pM} for a given experiment and factored into Eq. S3. Note that once the probability distribution
of cell counts {M0, · · · ,MN} is determined for a given realization of cell sizes {p1, · · · , pM}, all subsequent analysis and
derivations follow the same way as in the homogeneous cell size assumption.
Appendix C: Coinfection
As a vector for infection, the primary function of a single virus particle is to deliver its genetic contents into the host cell
cytoplasm or nucleus [10–12]. The typical model for viral infection assumes each virus contains all the genetic material required
to replicate within a host cell [14, 15]. Certain plant and fungi viruses, however, require two or more particles to successfully
replicate within a host cell since each particle contains only part of the complete genome [44]. Similarly, RNA viruses that target
animal cells undergo error prone replication, resulting in partially complete genome sequences. These damaged viral genes
may encode proteins needed for the host cell to successfully replicate new viruses. In this case, regardless of a successful viral
infection, new viruses capable of infecting further host cells will not be produced. Additional viral infections that contain the
missing sequence fragments, though, can “rescue” the cell’s ability to replicate the virus, a phenomenon known as coinfection.
In the context of our definition of SMOI, we now make the distinction betweenMr, the number of cells that have been infected
by viral genomes from exactly r distinct virus particles, and M∗r , the number of cells that are fully capable of replicating new
functioning viruses upon undergoing r distinct viral infections. It is immediate that each M∗r ≤ Mr and their sum M
∗ ≡∑N
r=1Mr ≤M −M0, so the results in Eqs. 9 and 12 are not sufficient to quantify the total number of virus-producing cells.
In order to model coinfection, we need to consider the genome of the virus species of interest. Specifically, we assume the
genome is made up of G distinct genes. For example, many variants of HIV-1 carry a gene sequence containing G = 9 genes
[10]. In our model, we assume each gene encodes a protein that is essential for replication. Though individual nucleotide
changes due to random mutations may result in an amino acid chain that is no longer functioning, some genes may be robust to
these changes due to codon degeneracy or the gene’s shear length [45]. Thus, we assume each gene g = 1, · · · , G contained
within a viral particle has a probability qg of losing function. If a cell is infected by exactly r viral genomes, we define B
r
g as
the event that gene g is still no longer functional, so that Pr(Brg) = q
r
g . To quantify the probability that k genes are no longer
functional in a host cell that has been infected by exactly r viral genomes, we use the inclusion-exclusion principle [41] to derive
Pr (“k failed genes given r infections”) =
G∑
j=k
(−1)j−k
(
j
k
) ∑
I⊂{1,··· ,G}
|I|=j
Pr

⋂
g∈I
Brg


=
G∑
j=k
(−1)j−k
(
j
k
) 1∑
σ1=0
· · ·
1∑
σG=0
1
∑
G
g=1 σg=j
G∏
g=1
qσgrg , (S1)
where 1∑G
g=1
σg=j
is an indicator function that returns zero when the number of nonzero σg is not exactly j. The infected cell is
only capable of producing viable viruses if none of the genes have failed and is equivalent to setting k = 0 in Eq. S1. Then we
define the probabilityHr that a cell infected by exactly r viral genomes will successfully produce new viruses as
Hr =
G∑
j=0
(−1)j
1∑
σ1=0
· · ·
1∑
σG=0
1
∑
G
g=1 σg=j
G∏
g=1
qσgrg . (S2)
Note that the probability that a cell not infected by any viral genome will produce viruses is H0 = 0. Then, given an SMOI
{M0, · · · ,MN}, the number of cellsM
∗
r capable of virus replication after being infected by exactly r viral genomes is binomi-
ally distributed with parametersMr andHr. The probability ofM
∗ cells producing viruses is given by
Pr (M∗ = m|M0, · · · ,MN ,M,N) =
∑
M∗
1
,··· ,M∗
N
(
m
M∗1 , · · · ,M
∗
N
) N∏
r=1
(
Mr
M∗r
)
H
M∗r
r (1−Hr)
Mr−M
∗
r . (S3)
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If we letm = 0 and sum over the density in Eq. 5 for all possible SMOI, given an IU countN , we can derive the probability of
observing a cytopathic effect as
Pr(“Cytopathic effect”|N) = 1−
∑
M0,··· ,MN
1
MN
(
M
M0, · · · ,MN
)(
N
0, · · · , 0, 1, · · · , 1, · · · , N, · · · , N
) N∏
r=1
(1−Hr)
Mr
= 1−
M !N !
MN
N∏
r=0
M∑
Mr=0
(1−Hr)
Mr
Mr!(r!)Mr
≈ 1−
M !N !
MN
exp
[
N∑
r=0
1−Hr
r!
]
, (S4)
where the approximation is due to the assumption that the number of cellsM is large. For intermediate values of N , computing
the summation in the exponential is numerically viable, assuming the probabilities of gene failure q1, · · · , qG are known. Though
this expression may be used in place of Eq. 12 to analyze some virus quantification assays, for large values of N , numerically
evaluatingHr becomes computationally expensive.
Appendix D: Viral Interference
To infect healthy cells, all species of viruses must undergo a series of events including cell attachment, entry via membrane
fusion or endocytosis, and intracellular transport. Retroviruses, such as HIV-1, must also undergo reverse transcription, nuclear
pore transport, and DNA integration in order to use the host cell’s transcription machinery to produce viral protein. In the
models developed in this paper, the probabilities of success for each of these processes was assumed to be subsumed into the a
priori estimated particle to PFU ratio Q. However, for certain retroviruses, it has been observed that after an initial infection,
subsequent infections from the same virus species become less likely [46, 47]. This phenomenon, known as viral interference,
is often due to the host producing new viral proteins after a refractory period that can inhibit one or more of the intracellular
processes leading to integration of subsequent viral infections. To include this dynamic into our models, we first decouple the
probabilities of integration from Q and define N as the number of viruses that have successfully completed viral entry into the
host cytoplasm, but before all intracellular processes that lead to integration. Note that all of our results concerning the statistical
multiplicity of infection (SMOI) still hold and we make the distinction between the numberMr of cells infected by r of the N
infectious units and the numberM∗s of cells with exactly s integrations. Furthermore, some species of virus can contain multiple
copies of their genome, such as HIV-1 which contains two copies per particle [10]. Let a be the number of genomes contained
in a single virus particle to be integrated into the host cell. Then the maximum number of possible integrations for a cell from
Mr is ra. Let ps be the probability of a viral genome integrating into the host DNA given that s − 1 integrations have already
occurred. Define Hr,s as the probability a cell contains s successful integrations given that it was infected by exactly r distinct
virus particles and is given by
Hr,s =
{
p1p2 · · · ps(1− ps+1)
ra−s 0 ≤ s ≤ ra
0 s > ra.
(S1)
If we define M∗r,s as the number of cells with s integrations after infection by exactly r virus particles, then given an SMOI
{M0, · · · ,MN} and N , we can derive the probability function
Pr(M∗r,s = m|M0, · · · ,MN , N) =
(
Mr
m
)
Hmr,s (1−Hr,s)
Mr−m . (S2)
Noting thatM∗s =
∑N
r=0M
∗
r,s is the number of cells with exactly s integrations, we can use Eqs. 6 and S2 to derive the expected
value as
E [M∗s |N ] =
N∑
r=0
E
[
M∗r,s|N
]
=
N∑
r=0
Hr,sE [Mr|N ]
=Me−µ
N∑
r=0
Hr,sµ
r
r!
, (S3)
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where µ = N
M
. Note that if we are concerned with the total numberM∗ = M −M∗0 of cells with at least one integration, as
is the case for the probability distributions derived for assays employing serial dilution, issue of viral interference is negligible,
allowing us to subsume the probability of the first integration into the particle to PFU ratio Q as before and leave all subsequent
virus quantification analysis unchanged from the results in Section IIIA and III B. However, for assays that attempts to quantify
the total number of integrations, such as the luciferase reporter assay, the expectation in Eq. S3 can be used, assuming the
probabilities p1, · · · , pN have a priori been estimated.
Appendix E: Sensitivity Analysis
The probability models derived in Section IIA allowed us to construct the likelihood functions for the plaque, endpoint dilu-
tion, and luciferase reporter assays in Eqs. 14, 20, and 27 for the primary purpose of inferring unknown parameters such as N0
and µ. The utility of these functions can be extended to performing sensitivity analysis on these maximum likelihood estimates
(MLE) and optimizing experimental design. This requires constructing a Fisher Information Matrix (FIM), a quantitative mea-
sure of the information one can extract for a likelihood function with an arbitrary set of data [48, 49]. The FIM, which we will
denote as J , is constructed by computing the gradient of the log of the likelihood function with respect to the parameters being
inferred. For example, for the plaque assay and potentially inferred parametersN0, Q, andM , J is given by
J = E
[
(∇ lnL) (∇ lnL)
T
]
=

JN0,N0 JN0,Q JN0,MJQ,N0 JQ,Q JQ,M
JM,N0 JM,Q JM,M

 , (S1)
where we derive
JN0,N0 = E
[(
∂ lnL
∂N0
)2]
=
dmax∑
d=dc
T exp
(
− N0
QMDd
)
Q2MD2d
[
1− exp
(
− N0
QMDd
)] , (S2)
JQ,Q = E
[(
∂ lnL
∂Q
)2]
=
dmax∑
d=dc
TN20 exp
(
− N0
QMDd
)
Q4MD2d
[
1− exp
(
− N0
QMDd
)] , (S3)
JM,M = E
[(
∂ lnL
∂M
)2]
=
dmax∑
d=dc
TN0 exp
(
− N0
QMDd
)
QM2Dd
[
1− exp
(
− N0
QMDd
)] , (S4)
JN0,Q = JQ,N0 = E
[(
∂ lnL
∂N0
)(
∂ lnL
∂Q
)]
= −
dmax∑
d=dc
TN0 exp
(
− N0
QMDd
)
Q3MD2d
[
1− exp
(
− N0
QMDd
)] , (S5)
JN0,M = JM,N0 = E
[(
∂ lnL
∂N0
)(
∂ lnL
∂M
)]
= −
dmax∑
d=dc
TN0 exp
(
− N0
QMDd
)
Q2M2D2d
[
1− exp
(
− N0
QMDd
)] , (S6)
JQ,M = JM,Q = E
[(
∂ lnL
∂Q
)(
∂ lnL
∂M
)]
=
dmax∑
d=dc
TN20 exp
(
− N0
QMDd
)
Q3M3D2d
[
1− exp
(
− N0
QMDd
)] . (S7)
In particular, the elements of the main diagonal of J , known as Fisher Information Numbers, are interpreted as the “precision”
of each MLE and can inform an experimentalist of the potential variation in their inferred parameter with respect to data defined
by the likelihood function. Comparing the main diagonal elements can offer insight into experimental design. To illustrate, in
the example above, it is immediately apparent that the ratio of JQ,Q to JN0,N0 is N
2
0 /Q
2, where it is understood that N0 is
typically several orders of magnitude higher than Q. This implies that the likelihood function of Eq. 14, and, by extension, the
plaque assay itself contains far more information about the parameter Q than N0. This provides an analytical way to decide
which parameter estimation should be the focus of a particular assay.
A more general use for the FIM is to understand the variance of an MLE given an arbitrary set of data. Independent, but
identical experiments can produce different estimates for each parameter and, according to the Cramer-Rao inequality, the matrix
inverse J−1 will provide a theoretical lower bound on the covariance matrix of the parameter estimates [48]. Furthermore, it can
be shown that the distribution of MLEs asymptotically approaches a normal distribution centered around the true experimental
parameter value with covariance J−1 as the amount of data increases [50]. For single point estimation, the FIM reduces to the
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one Fisher Information Number with which the reciprocal can be used to approximate the variance of a parameter. For example,
the plaque assay is typically used to infer only the parameterN0, so using Eq. S2, we can obtain the asymptotic approximation
Var
[
Nˆ0
]
≈ J−1N0,N0 =

dmax∑
d=dc
T exp
(
− N0
QMDd
)
Q2MD2d
[
1− exp
(
− N0
QMDd
)]


−1
. (S8)
This analytical expression for the variance can be used to determine confidence intervals of the MLE, perform sensitivity analysis
of other parameters, and aid in optimal experimental design.
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